Literature DB >> 11745939

Antibodies against human papillomavirus (HPV) type 16 and 18 E2, E6 and E7 proteins in sera: correlation with presence of papillomavirus DNA.

R Rosales1, M López-Contreras, R R Cortes.   

Abstract

Human papillomavirus (HPV) infection is associated with cervical cancer. The E2 and E1 papillomavirus proteins are expressed at the early stage of infection and regulate DNA replication. The E2 protein activates and represses transcription from different HPVs promoters. At some stage when viral DNA gets integrated into the cellular genome, the E2 gene is disrupted or inactivated. This event leads to a derepression of the E6 and E7 viral oncogenes. These viral proteins are required normally for the maintenance of the malignant phenotype. Therefore, the E2, E6, and E7 proteins are present in all patients infected by papillomavirus. In this study, the association of antibody levels against E2, E6, and E7 proteins of HPV types 16, 18, and 6 was determined in relation to the presence of HPV DNA at the initial stages of HPV infection. Serum samples from 172 women with HPV infection, determined by Papanicolau (Pap) smears and colposcopy, were tested. Elevated antibody titers against E2 protein from the HPV 6 and HPV 16 were detected in 46.42 and 66.96% of the patients, respectively. Antibodies against the E7 and E6 proteins of HPV 16 were found in 51.78 and 36.60% of the patients, respectively. Antibodies against the E6 and E7 proteins of HPV 18 were 35 and 45%, respectively. A statistical difference was found for antibody titers against the E2, E6, and E7 proteins between patients with papillomavirus DNA and controls cases who had no cytological abnormalities and no HPV DNA. Sera titers were 1/500 for patients HPV positive and 1/50 for control individuals. Antibodies titers against E6 and E7 proteins were also examined in patients at 6 and 24 months after cryosurgery. In these patients, a slight decrease in the antibody level against the E2, E6, and E7 proteins was found. No correlation was found between age and number of sexual partners, with serum positivity to the E2, E6, and E7 papillomavirus proteins. These data suggest that antibodies against the E2, E6, and E7 proteins are good candidates for use as markers for monitoring cervical HPV infections. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11745939     DOI: 10.1002/jmv.2098

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  9 in total

1.  HPV Serum Antibodies as Predictors of Survival and Disease Progression in Patients with HPV-Positive Squamous Cell Carcinoma of the Oropharynx.

Authors:  Kristina R Dahlstrom; Karen S Anderson; Julia N Cheng; Diego Chowell; Guojun Li; Marshall Posner; Erich M Sturgis
Journal:  Clin Cancer Res       Date:  2015-06-15       Impact factor: 12.531

2.  High-throughput profiling of the humoral immune responses against thirteen human papillomavirus types by proteome microarrays.

Authors:  Martha Luevano; Hans-Ulrich Bernard; Hugo A Barrera-Saldaña; Victor Trevino; Alejandro Garcia-Carranca; Luisa L Villa; Bradley J Monk; Xiaolin Tan; D Huw Davies; Phil L Felgner; Mina Kalantari
Journal:  Virology       Date:  2010-06-15       Impact factor: 3.616

3.  Association of antibody to E2 protein of human papillomavirus and p16INK4A with progression of HPV-infected cervical lesions.

Authors:  Jureeporn Chuerduangphui; Chamsai Pientong; Piyawut Swangphon; Sanguanchoke Luanratanakorn; Ussanee Sangkomkamhang; Thumwadee Tungsiriwattana; Pilaiwan Kleebkaow; Ati Burassakarn; Tipaya Ekalaksananan
Journal:  Med Oncol       Date:  2018-05-09       Impact factor: 3.064

4.  A novel HPV 16 L1-based chimeric virus-like particle containing E6 and E7 seroreactive epitopes permits highly specific detection of antibodies in patients with CIN 1 and HPV-16 infection.

Authors:  Alberto Monroy-García; Miguel A Gómez-Lim; Benny Weiss-Steider; Georgina Paz-de la Rosa; Jorge Hernández-Montes; Karyna Pérez-Saldaña; Yessica S Tapia-Guerrero; Mariel E Toledo-Guzmán; Edelmiro Santiago-Osorio; Héctor I Sanchez-Peña; María de Lourdes Mora-García
Journal:  Virol J       Date:  2011-02-09       Impact factor: 4.099

5.  Serum antibodies to the HPV16 proteome as biomarkers for head and neck cancer.

Authors:  K S Anderson; J Wong; G D'Souza; A B Riemer; J Lorch; R Haddad; S I Pai; J Longtine; M McClean; J LaBaer; K T Kelsey; M Posner
Journal:  Br J Cancer       Date:  2011-06-07       Impact factor: 7.640

Review 6.  Immunotherapy for HPV associated cancer.

Authors:  Ian H Frazer; Janin Chandra
Journal:  Papillomavirus Res       Date:  2019-07-13

7.  Detection of Immunoglobulin G against E7 of Human Papillomavirus in Non-Small-Cell Lung Cancer.

Authors:  Raul Storey; Joongho Joh; Amy Kwon; A Bennett Jenson; Shin-Je Ghim; Goetz H Kloecker
Journal:  J Oncol       Date:  2013-03-03       Impact factor: 4.375

8.  The Cancer-Associated Virus Landscape in HIV Patients with Oral Hairy Leukoplakia, Kaposi's Sarcoma, and Non-Hodgkin Lymphoma.

Authors:  Peter D Burbelo; Joseph A Kovacs; Jason Wagner; Ahmad Bayat; Craig S Rhodes; Yvonne De Souza; John S Greenspan; Michael J Iadarola
Journal:  AIDS Res Treat       Date:  2012-08-08

9.  New Approaches to Immunotherapy for HPV Associated Cancers.

Authors:  Anne-Sophie Bergot; Andrew Kassianos; Ian H Frazer; Deepak Mittal
Journal:  Cancers (Basel)       Date:  2011-09-02       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.